Plasmapheresis News and Research RSS Feed - Plasmapheresis News and Research

Doctor receives international patents for therapeutic process to remove excess galectin-3

Doctor receives international patents for therapeutic process to remove excess galectin-3

Isaac Eliaz, MD, MS, LAc has been awarded a USA patent as well as additional international patents for a therapeutic process that allows for the removal of excess galectin-3 from the circulatory system using plasmapheresis. [More]
Biotest Pharmaceuticals opens new plasma collection center in Valdosta, Georgia

Biotest Pharmaceuticals opens new plasma collection center in Valdosta, Georgia

Biotest Pharmaceuticals Corporation, a leading developer of immunology biotherapeutic products, is pleased to announce the addition of its newest plasma collection center located at 311 North Patterson Road, in Valdosta, Georgia. [More]
Researchers discover new therapeutic approach for hemophilia

Researchers discover new therapeutic approach for hemophilia

Researchers at the UNC School of Medicine and the Medical College of Wisconsin found that a new kind of gene therapy led to a dramatic decline in bleeding events in dogs with naturally occurring hemophilia A, a serious and costly bleeding condition that affects about 50,000 people in the United States and millions more around the world. [More]
Researchers overcome obstacle to using viruses to deliver therapeutic genes

Researchers overcome obstacle to using viruses to deliver therapeutic genes

Scientists in The Research Institute at Nationwide Children's Hospital have found a way to overcome one of the biggest obstacles to using viruses to deliver therapeutic genes: how to keep the immune system from neutralizing the virus before it can deliver its genetic payload. In a study published recently in Molecular Therapy, researchers found that giving subjects a treatment to temporarily rid the body of antibodies provides the virus safe passage to targeted cells, allowing it to release a corrective or replacement gene to treat disease. [More]

FDA clears Fenwal's Aurora plasmapheresis system

The U.S. Food and Drug Administration has cleared for marketing a new source plasma collection system developed by Fenwal, Inc., the company announced today. Called the Aurora plasmapheresis system, the new device can support two-way, wireless data communication designed to eliminate manual steps and increase operator and donor satisfaction. [More]
Better medical care for kidney failure in Germany

Better medical care for kidney failure in Germany

In complex cases of kidney failure, medical care in Germany evidently operates better than in the US. Scientists at Charité - Universitätsmedizin Berlin were able to show that German patients who have an increased risk of rejection reactions due to prior immunization have better survival rates than people with diseases of similar severity in the US. [More]
FDA approves Abbott's new Chagas in vitro diagnostic test

FDA approves Abbott's new Chagas in vitro diagnostic test

Abbott received approval from the U.S. Food and Drug Administration (FDA) for a new Chagas in vitro diagnostic test. [More]
Novel blood-cleaning procedure allows receipt of transplant from different blood type donor

Novel blood-cleaning procedure allows receipt of transplant from different blood type donor

St. Michael's Hospital today became the first in North America to use a novel blood-cleaning procedure for a kidney patient that will allow him to receive a transplant from a donor with a different blood type. [More]
FTC accepts Grifols and Talecris' Consent Agreement for public comment

FTC accepts Grifols and Talecris' Consent Agreement for public comment

Grifols, S.A. and Talecris Biotherapeutics Holdings Corp. announced today that the U.S. Federal Trade Commission has accepted for public comment a Consent Agreement that outlines the conditions necessary for Grifols' acquisition of Talecris to proceed. [More]
Eculizumab effective for treating hemolytic-uremic syndrome from EHEC

Eculizumab effective for treating hemolytic-uremic syndrome from EHEC

In the online version of the New England Journal of Medicine, physicians and scientists in Heidelberg, Montreal, and Paris reported on the successful treatment of three young children who were suffering from a severe hemolytic-uremic syndrome after an infection with enterohemorrhagic Escherichia coli. [More]
Pending merger transaction between Grifols, Talecris has been extended

Pending merger transaction between Grifols, Talecris has been extended

Grifols S.A. and Talecris Biotherapeutics Holdings Corp. today announced that the outside date under their merger agreement for closing their pending merger transaction has been extended to June 30, 2011 (from March 6, 2011). [More]
Grifols to start construction of new plant in Spain for plasma fractionation

Grifols to start construction of new plant in Spain for plasma fractionation

Grifols, the Spanish group which specializes in the hospital-pharmaceutical sector and is one of the world's leading producers of plasma products, will shortly start construction of a new plant representing an investment of 20 million euros that will employ about 100 people, as soon as it obtains local permits and licenses. [More]
New guideline recommends plasmapheresis usage to treat people with severe relapses in MS, neuropathies

New guideline recommends plasmapheresis usage to treat people with severe relapses in MS, neuropathies

A new guideline from the American Academy of Neurology recommends using plasma exchange to treat people with severe relapses in multiple sclerosis and related diseases, as well as those with certain kinds of nerve disorders known as neuropathies. [More]
Researchers develop new therapy to overcome tissue incompatibility in kidney transplantation

Researchers develop new therapy to overcome tissue incompatibility in kidney transplantation

Donor kidneys can be successfully transplanted even if there is strong tissue incompatibility between donor and recipient. An interdisciplinary working group headed by Dr. Christian Morath, senior consultant at the Department of Nephrology at Heidelberg University Hospital (Medical Director: Professor Dr. Martin Zeier) and Professor Dr. Caner S-sal, head of antibody laboratory in the Department of Transplantation Immunology, showed in a study of 34 sensitized high-risk patients that the success rate in these patients was not different from the success rate of patients with a low immunological risk. [More]
NIH awards three grants to explore novel treatment strategies for muscular dystrophy

NIH awards three grants to explore novel treatment strategies for muscular dystrophy

Three grants totaling more than $4.5 million, from agencies of the National Institutes of Health, will be used to explore novel treatment strategies for muscular dystrophy. [More]
British, Austrian scientists awarded K. J. Zülch Prize for basic neurological research

British, Austrian scientists awarded K. J. Zülch Prize for basic neurological research

British and Austrian scientists receive award for basic neurological research. Alastair Compston and Hans Lassmann are this year's recipients of the K. J. Zülch Prize for basic neurological research. In bestowing this award, the Gertrud Reemtsma Foundation is honouring two scientists who have made crucial contributions to research on multiple sclerosis. Alastair Compston's work has provided important insights into the genetics and treatment of multiple sclerosis. [More]

Octapharma completes clinical development of Uniplas human pooled plasma

Octapharma AG, one of the largest private manufacturers of plasma products in the world, announced today that the clinical development for Uniplas® has been successfully completed. The product has been filed for registration in Europe and will be submitted later in the USA. [More]
Grifols to acquire Pharmalink's Xepol programme for post-polio syndrome

Grifols to acquire Pharmalink's Xepol programme for post-polio syndrome

Pharmalink AB, today announced that it has closed its agreement with Grifols SA for the acquisition of Pharmalink's Xepol(R) programme for the treatment of post-polio syndrome (PPS). The parties had previously announced reaching an agreement whereby Grifols would acquire all know-how and global intellectual property rights related to the use of human immunoglobulin for the treatment of (PPS) - the concept at the heart of the Xepol programme. [More]
Grifols reaches agreement with Pharmalink to acquire PPS drug development project

Grifols reaches agreement with Pharmalink to acquire PPS drug development project

Today, Grifols SA announced that it has reached an agreement with the Swedish company Pharmalink AB to acquire various forms of intellectual property associated with the treatment of post-polio syndrome. The acquisition is expected to be finalized in the next few weeks and will include documentation, know-how, and Swedish regulatory approvals under the trade name Xepol. [More]
ABBOTT PRISM Chagas test receives FDA approval

ABBOTT PRISM Chagas test receives FDA approval

Abbott received Biologic License Application (BLA) approval from the United States Food and Drug Administration (FDA) for the ABBOTT PRISM Chagas test. The test is a fully automated blood screening assay that can detect antibodies to Trypansoma cruzi (T. cruzi), a parasite found only in the Americas and most commonly acquired through contact with the blood-sucking triatomine or "kissing bug." [More]